関: coronary restenosis

WordNet

(botany) the trumpet-shaped or cup-shaped outgrowth of the corolla of a daffodil or narcissus flower
one or more circles of light seen around a luminous object
a long cigar with blunt ends
(anatomy) any structure that resembles a crown in shape
a major thoroughfare that bears important traffic
a blood vessel that carries blood from the heart to the body (同)arteria, arterial blood vessel
surrounding like a crown (especially of the blood vessels surrounding the heart); "coronary arteries"

PrepTutorEJDIC

コロナ(皆既日食のときに見える光冠) / (太陽・月などの)かさ
動脈 / (道路・水路・鉄道などの)勘線,(通信の)主チャンネル
冠状動脈の / 心臓の / 冠状動脈血栓(けっせん)症(coronary thrombosis)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 冠動脈ステント再狭窄 intracoronary stent restenosis
2. 経皮的冠動脈形成術後の再狭窄予防のための長期内科的治療が果たし得る役割 possible role of long term medical therapies to prevent restenosis following percutaneous coronary intervention
3. 薬剤溶出性冠動脈ステントの使用 use of drug eluting intracoronary stents
4. 魚油と海洋由来オメガ3脂肪酸 fish oil and marine omega 3 fatty acids
5. ST上昇型心筋梗塞におけるプライマリ経皮的冠動脈インターベンションと血栓溶解療法
の比較：臨床試験 primary percutaneous coronary intervention versus fibrinolysis in acute st elevation myocardial infarction clinical trials

English Journal

The formation of an anti-restenotic/anti-thrombotic surface by immobilization of nitric oxide synthase on a metallic carrier.

Alagem-Shafir M1, Kivovich E2, Tzchori I3, Lanir N4, Falah M3, Flugelman MY5, Dinnar U1, Beyar R6, Lotan N1, Sivan SS7.Author information 1Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.2Department of Biotechnology Engineering, ORT Braude College of Engineering, Karmiel 21982, Israel.3Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.4Ruth and Bruce Rappaport faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.5Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel; Ruth and Bruce Rappaport faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.6Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel; Ruth and Bruce Rappaport faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Rambam Health Care Campus, Haifa, Israel.7Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel; Department of Biotechnology Engineering, ORT Braude College of Engineering, Karmiel 21982, Israel. Electronic address: sivan.sarit@gmail.com.AbstractCoronary stenosis due to atherosclerosis, the primary cause of coronary artery disease, is generally treated by balloon dilatation and stent implantation, which can result in damage to the endothelial lining of blood vessels. This leads to the restenosis of the lumen as a consequence of migration and proliferation of smooth muscle cells (SMCs). Nitric oxide (NO), which is produced and secreted by vascular endothelial cells (ECs), is a central anti-inflammatory and anti-atherogenic player in the vasculature. The goal of the present study was to develop an enzymatically active surface capable of converting the prodrug l-arginine, to the active drug, NO, thus providing a targeted drug delivery interface. NO synthase (NOS) was chemically immobilized on the surface of a stainless steel carrier with preservation of its activity. The ability of this functionalized NO-producing surface to prevent or delay processes involved in restenosis and thrombus formation was tested. This surface was found to significantly promote EC adhesion and proliferation while inhibiting that of SMCs. Furthermore, platelet adherence to this surface was markedly inhibited. Beyond the application considered here, this approach can be implemented for the local conversion of any systemically administered prodrug to the active drug, using catalysts attached to the surface of the implant.
Acta biomaterialia.Acta Biomater.2014 May;10(5):2304-12. doi: 10.1016/j.actbio.2013.12.043. Epub 2013 Dec 31.
Coronary stenosis due to atherosclerosis, the primary cause of coronary artery disease, is generally treated by balloon dilatation and stent implantation, which can result in damage to the endothelial lining of blood vessels. This leads to the restenosis of the lumen as a consequence of migration an
PMID 24389316

Immobilization of heparin/poly-l-lysine nanoparticles on dopamine-coated surface to create a heparin density gradient for selective direction of platelet and vascular cells behavior.

Liu T1, Liu Y1, Chen Y1, Liu S2, Maitz MF3, Wang X1, Zhang K1, Wang J1, Wang Y1, Chen J4, Huang N1.Author information 1Key Laboratory of Advanced Technology of Materials, Ministry of Education, Southwest Jiaotong University, Chengdu 610031, People's Republic of China.2Key Laboratory of Advanced Technology of Materials, Ministry of Education, Southwest Jiaotong University, Chengdu 610031, People's Republic of China; Naton Medical Group, Peking 100082, People's Republic of China.3Key Laboratory of Advanced Technology of Materials, Ministry of Education, Southwest Jiaotong University, Chengdu 610031, People's Republic of China; Leibniz Institute of Polymer Research Dresden, Max Bergmann Center of Biomaterials, Hohe Str. 06, 01069 Dresden, Germany.4Key Laboratory of Advanced Technology of Materials, Ministry of Education, Southwest Jiaotong University, Chengdu 610031, People's Republic of China. Electronic address: chenjy@263.net.AbstractRestenosis, thrombosis formation and delayed endothelium regeneration continue to be problematic for coronary artery stent therapy. To improve the hemocompatibility of the cardiovascular implants and selectively direct vascular cell behavior, a novel kind of heparin/poly-l-lysine (Hep/PLL) nanoparticle was developed and immobilized on a dopamine-coated surface. The stability and structural characteristics of the nanoparticles changed with the Hep:PLL concentration ratio. A Hep density gradient was created on a surface by immobilizing nanoparticles with various Hep:PLL ratios on a dopamine-coated surface. Antithrombin III binding quantity was significantly enhanced, and in plasma the APTT and TT times as coagulation tests were prolonged, depending on the Hep density. A low Hep density is sufficient to prevent platelet adhesion and activation. The sensitivity of vascular cells to the Hep density is very different: high Hep density inhibits the growth of all vascular cells, while low Hep density could selectively inhibit smooth muscle cell hyperplasia but promote endothelial progenitor cells and endothelial cell proliferation. These observations provide important guidance for modification of surface heparinization. We suggest that this method will provide a potential means to construct a suitable platform on a stent surface for selective direction of vascular cell behavior with low side effects.
Acta biomaterialia.Acta Biomater.2014 May;10(5):1940-54. doi: 10.1016/j.actbio.2013.12.013. Epub 2013 Dec 14.
Restenosis, thrombosis formation and delayed endothelium regeneration continue to be problematic for coronary artery stent therapy. To improve the hemocompatibility of the cardiovascular implants and selectively direct vascular cell behavior, a novel kind of heparin/poly-l-lysine (Hep/PLL) nanoparti
PMID 24342042

Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease.

Machado C1, Raposo L, Dores H, Leal S, Campante Teles R, de Araújo Gonçalves P, Mesquita Gabriel H, Almeida M, Mendes M.Author information 1aDepartment of Cardiology, Santa Cruz Hospital, Lisbon bDepartment of Cardiology, Divino Espírito Santo Hospital, Ponta Delgada, Portugal.AbstractINTRODUCTION AND AIMS: Randomized trials and registries have shown that drug-eluting stents (DES) have an overall better performance than bare-metal stents in patients treated in the setting of both ST-segment and non-ST-segment elevation acute coronary syndromes, mainly by reducing restenosis. Whether or not the use of newer second-generation devices (vs. first-generation DES) differs in these high-risk patients remains to be determined.
Coronary artery disease.Coron Artery Dis.2014 May;25(3):208-14. doi: 10.1097/MCA.0000000000000078.
INTRODUCTION AND AIMS: Randomized trials and registries have shown that drug-eluting stents (DES) have an overall better performance than bare-metal stents in patients treated in the setting of both ST-segment and non-ST-segment elevation acute coronary syndromes, mainly by reducing restenosis. Whet
PMID 24419038

Japanese Journal

Contributors to Newly Developed Coronary Artery Disease in Patients with a Previous History of Percutaneous Coronary Intervention beyond the Early Phase of Restenosis

Endo Akihiro,Yoshida Yasuyuki,Kageshima Kenji,Sato Hirotomo,Suga Toshimitsu,Nasu Hiroshi,Takahashi Nobuyuki,Tanabe Kazuaki
Internal Medicine 53(8), 819-828, 2014
… however, in patients with a previous history of percutaneous coronary intervention (PCI), there is little information regarding the predictive value of this parameter beyond the period of early restenosis. … The aim of this study was to investigate contributing factors to newly developed coronary artery disease in patients with a previous history of PCI after stabilization. …
NAID 130003392769

Adipose-Derived Stem Cells Stimulate Reendothelialization in Stented Rat Abdominal Aorta

Sato Tomohiko,Takahashi Masao,Fujita Daishi,Oba Shigeyoshi,Nishimatsu Hiroaki,Nagano Tetsuo,Suzuki Etsu
Circulation Journal, 2014
… Background: Although drug-eluting stents (DES) have been widely used for the treatment of coronary artery disease, they potentially increase the risk of late thrombosis. … Endothelial injury models have been widely used to analyze the mechanisms of coronary restenosis. …
NAID 130003391139

Effect of Bare-Metal Nitinol Stent Implantation and Paclitaxel-Eluting Nitinol Stent Implantation on Vascular Response in the Superficial Femoral Artery Lesion Assessed on Intravascular Ultrasound

Miki Kojiro,Fujii Kenichi,Kawasaki Daizo,Fukunaga Masashi,Nishimura Machiko,Horimatsu Tetsuo,Saita Ten,Tamaru Hiroto,Imanaka Takahiro,Shibuya Masahiko,Masutani Motomaru,Ohyanagi Mitsumasa,Masuyama Tohru
Circulation Journal, 2014
… Background: Although previous intravascular ultrasound (IVUS) studies reported that the drug-eluting stent (DES) has successfully decreased in-stent restenosis (ISR) by inhibiting neointimal hyperplasia (NIH) in the coronary artery lesion, no IVUS data for vascular response after DES implantation in the superficial femoral artery (SFA) have been published. …
NAID 130003391128